サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1427736

カペシタビンの世界市場レポート 2024

Capecitabine Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
カペシタビンの世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

カペシタビンの市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には8.7%の年間複合成長率（CAGR）で31億4,000万米ドルに成長すると予想されます。予測期間で予想される成長は、カペシタビンの適応症の拡大、併用療法の進行中の調査、ヘルスケアインフラの開発、がん治療を支援する政府の取り組み、新興諸国での導入の増加などの要因に起因すると考えられます。予測期間中に予想される注目すべき動向としては、標的療法の組み合わせの探求、アジュバント設定での使用の拡大、バイオマーカー主導の治療アプローチの統合、薬理ゲノミクスの進歩、がん治療における遠隔医療モニタリングの導入などが挙げられます。これらの動向は、がん治療に対する個別化された包括的なアプローチに焦点を当てたダイナミックな情勢を示しています。

予測されるがん症例の増加は、カペシタビン市場の拡大の主要な推進力になると予想されます。がんは、異常な細胞増殖を特徴とする多様な疾患であり、多くの場合制御不能に広がり、さまざまな臓器や組織にわたって重大な健康上の課題を引き起こします。化学療法剤であるカペシタビンは、腫瘍内で酵素的に代謝拮抗物質のフルオロウラシルに変換することで、がん治療において重要な役割を果たします。この変換はDNA合成を阻害し、腫瘍組織の増殖を効果的に遅らせます。特に、2021年に米国がん協会が報告した米国における新たながん罹患者数は約190万人、がん関連死亡者数は608,570人で、2020年に報告された新たながん罹患者数180万人、死亡者数606,520人から増加している。このがん罹患率の上昇が、カペシタビン市場の拡大を促す主な要因となっています。

臨床試験の急増は、カペシタビン市場の成長軌道に大きな影響を与える可能性があります。臨床試験は、ヒトを対象とした医療介入や薬剤の安全性と有効性を評価する極めて重要な調査であり、さまざまな種類のがんに対するカペシタビンの可能性を評価する上で重要な役割を果たします。これらの試験は医薬品開発プロセスの基本的な段階を構成し、規制当局の承認と最終的な一般使用に不可欠なデータを提供します。カナダの広告サービス会社Xtalksのレポートによると、2023年 5月の時点で、ClinicalTrials.govに世界的に452,604件の臨床試験が登録されており、これまでに報告された2021年初頭の365,000件以上の臨床試験から大幅に増加していることが示されています。この臨床試験の急増は、臨床試験の増加を強調しています。 カペシタビンの潜在的なアプリケーションを推進する上で極めて重要な役割を果たし、結果的にカペシタビン市場の成長を促進します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のカペシタビン市場、医薬品タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • ブランド
  • ジェネリック
  • 世界のカペシタビン市場、医薬品剤形別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 錠剤
  • カプセル
  • 世界のカペシタビン市場、流通チャネル別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • 病院薬局
  • オンライン薬局
  • 小売薬局
  • 世界のカペシタビン市場、用途別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • 結腸がん
  • 直腸がん
  • 乳がん
  • 胃がん
  • その他の用途
  • 世界のカペシタビン市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • 病院
  • 在宅ケア
  • 専門センター
  • その他のエンドユーザー

第7章 地域および国の分析

  • 世界のカペシタビン市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
  • 世界のカペシタビン市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • カペシタビン市場の競合情勢
  • カペシタビン市場の企業プロファイル
    • Pfizer Inc.
    • Merck &Co. Inc.
    • Bayer AG
    • Novartis AG
    • Sanofi SA

第31章 その他の大手および革新的な企業

  • Sensus Healthcare Inc.
  • Fresenius SE &Co. KGaA
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Inc.
  • Genentech Inc.
  • Aurobindo Pharma Limited
  • Dr Reddy Laboratories Ltd.
  • Sigma-Aldrich Corp
  • Cipla Inc.
  • Hikma Pharmaceuticals plc
  • Lupin Limited
  • Alkem Laboratories Limited
  • Ranbaxy Laboratories Ltd.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13580

Capecitabine is a chemotherapeutic drug designed to inhibit DNA synthesis and reduce the growth of tumor tissue. It achieves this by enzymatically transforming into the antimetabolite fluorouracil within the tumor. Administered orally, capecitabine is used in the treatment of metastatic breast and colorectal cancers.

Capecitabine drugs come in two main types such as branded and generic. Branded drugs are medical substances available only with a prescription from a qualified physician or authorized prescriber, following state or federal regulations. These drugs are used either alone or in combination to address metastatic colon cancer. Various formulations, such as tablets and capsules, make up the drug forms, and they are distributed through channels including hospital pharmacies, online pharmacies, and retail pharmacies. Capecitabine is applied in diverse medical contexts, including the treatment of colon cancer, rectal cancer, breast cancer, gastric cancer, and more. End-users encompass hospitals, homecare services, specialty centers, and other healthcare providers.

The capecitabine market research report is one of a series of new reports from The Business Research Company that provides capecitabine market statistics, including capecitabine industry global market size, regional shares, competitors with a capecitabine market share, detailed capecitabine market segments, market trends and opportunities, and any further data you may need to thrive in the capecitabine industry. This capecitabine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The capecitabine market size has grown strongly in recent years. It will grow from $2.06 billion in 2023 to $2.25 billion in 2024 at a compound annual growth rate (CAGR) of 9.4%. The growth observed in the historic period can be attributed to advancements in chemotherapy, the convenience offered by oral administration, regulatory approvals, improved accessibility to treatments, and recommendations from oncologists. These factors collectively contributed to the increased adoption and utilization of capecitabine in the management of metastatic breast and colorectal cancers. The evolution of chemotherapy practices, coupled with the convenience of oral delivery, played a significant role in shaping the historical growth trajectory of capecitabine.

The capecitabine market size is expected to see strong growth in the next few years. It will grow to $3.14 billion in 2028 at a compound annual growth rate (CAGR) of 8.7%. The anticipated growth in the forecast period can be attributed to factors such as expanded indications for capecitabine, ongoing research in combination therapies, development of healthcare infrastructure, government initiatives supporting cancer care, and increased adoption in developing countries. Notable trends expected in the forecast period include the exploration of targeted therapy combinations, expanded use in adjuvant settings, the integration of biomarker-driven treatment approaches, advancements in pharmacogenomics, and the implementation of telehealth monitoring in cancer care. These trends indicate a dynamic landscape with a focus on personalized and comprehensive approaches to cancer treatment.

The projected rise in cancer cases is anticipated to be a major driver behind the expansion of the capecitabine market. Cancer, a diverse spectrum of diseases characterized by abnormal cell growth that often spreads uncontrollably, poses a significant health challenge across various organs and tissues. Capecitabine, a chemotherapeutic agent, plays a crucial role in cancer treatment by enzymatically transforming into the antimetabolite fluorouracil within tumors. This conversion inhibits DNA synthesis, effectively slowing down the growth of tumor tissue. Notably, in 2021, the American Cancer Society reported approximately 1.9 million new cancer cases and 608,570 cancer-related deaths in the United States, marking an increase from the 1.8 million new cases and 606,520 deaths reported in 2020. This escalating incidence of cancer serves as a primary factor driving the expansion of the capecitabine market.

The upsurge in clinical trials stands poised to significantly impact the growth trajectory of the capecitabine market. Clinical trials, pivotal research studies evaluating the safety and efficacy of medical interventions or drugs in human subjects, play a crucial role in assessing capecitabine's potential across diverse cancer types. These trials constitute a fundamental phase in the drug development process, providing essential data for regulatory approval and eventual public use. As of May 2023, reports from Xtalks, a Canadian advertising services company, indicate a global registration of 452,604 clinical trials on ClinicalTrials.gov, signifying a substantial increase from the previously reported over 365,000 trials in early 2021. This surge in clinical trials underscores their pivotal role in advancing capecitabine's potential applications, consequently fueling the growth of the capecitabine market.

The trend of product innovations has gained significant traction. Notably, major companies operating within the capecitabine market have directed their efforts towards developing generic tablets as a strategic approach to augment their revenues. A prime example occurred in February 2021 when Dr. Reddy's Laboratories, an India-based pharmaceutical company, introduced Capecitabine tablets-an FDA-approved generic variant of Xeloda-into the United States market. Specifically utilized in cancer treatment, these tablets are available in 150 mg and 500 mg strengths, offered in bottle counts of 60 and 120, respectively.

Prominent companies are focusing on the development of innovative drug formulations, such as dispersible tablets, aimed at enhancing patient compliance and securing a competitive advantage. Dispersible tablets represent a pharmaceutical dosage form designed for rapid dissolution in liquid for convenient administration. An illustrative instance took place in December 2022, when Shilpa Medicare Ltd., an India-based pharmaceutical company, launched Capecitabine 1000 MG under the brand Capebel. Distinguished as the world's inaugural dispersible tablet tailored for colorectal and metastatic breast cancer, this innovative product utilizes advanced technology for swift dispersion within a remarkable 90-second timeframe. As such its existing counterparts in 500 mg and 150 mg strengths, this novel tablet allows patients to dissolve it in 100 ml of water, offering a more manageable solution, particularly beneficial for cancer patients contending with swallowing difficulties. Such pioneering formulations exemplify a strategic approach adopted by companies within the capecitabine market to cater to patient needs while introducing groundbreaking pharmaceutical solutions.

In January 2023, Cheplapharm Arzneimittel GmbH, a pharmaceutical company based in Germany, completed the acquisition of the commercial rights for Xeloda (capecitabine) in China from F. Hoffmann-La Roche AG, a healthcare company based in Switzerland. The transaction, conducted for an undisclosed amount, is part of Cheplapharm's strategic efforts to fortify its oncology portfolio and expand its footprint in the pharmaceutical market. F. Hoffmann-La Roche AG is the producer of Xeloda, an oral chemotherapy drug containing capecitabine.

Major companies operating in the capecitabine market report are Pfizer Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Sensus Healthcare Inc., Fresenius SE & Co. KGaA, GlaxoSmithKline PLC, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Inc., Genentech Inc., Aurobindo Pharma Limited, Dr Reddy Laboratories Ltd., Sigma-Aldrich Corp, Cipla Inc., Hikma Pharmaceuticals PLC, Lupin Limited, Alkem Laboratories Limited, Ranbaxy Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Accord Healthcare Ltd., Zentiva N.V., Reliance Life Sciences Pvt Ltd., Avita Medical Limited, Mylan Inc., Sandoz Inc.

North America was the largest region in the capecitabine market in 2023. The regions covered in the capecitabine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the capecitabine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The capecitabine market consists of sales of croscarmellose sodium, anhydrous lactose, hydroxypropyl methylcellulose, magnesium stearate, and microcrystalline cellulose. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Capecitabine Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on capecitabine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for capecitabine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The capecitabine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Drug Type: Branded; Generic
  • 2) By Drug Formulation: Tablet; Capsules
  • 3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
  • 4) By Application: Colon Cancer; Rectal Cancer; Breast Cancer; Gastric Cancer; Other Applications
  • 5) By End-Users: Hospitals; Homecare; Specialty Centers; Other End-Users
  • Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Bayer AG; Novartis AG; Sanofi S.A.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Capecitabine Market Characteristics

3. Capecitabine Market Trends And Strategies

4. Capecitabine Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Capecitabine Market Size and Growth

  • 5.1. Global Capecitabine Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Capecitabine Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Capecitabine Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Capecitabine Market Segmentation

  • 6.1. Global Capecitabine Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Branded
  • Generic
  • 6.2. Global Capecitabine Market, Segmentation By Drug Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Tablet
  • Capsules
  • 6.3. Global Capecitabine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • 6.4. Global Capecitabine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Colon Cancer
  • Rectal Cancer
  • Breast Cancer
  • Gastric Cancer
  • Other Applications
  • 6.5. Global Capecitabine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Homecare
  • Specialty Centers
  • Other End-Users

7. Capecitabine Market Regional And Country Analysis

  • 7.1. Global Capecitabine Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Capecitabine Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Capecitabine Market

  • 8.1. Asia-Pacific Capecitabine Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Capecitabine Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Capecitabine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Capecitabine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Capecitabine Market

  • 9.1. China Capecitabine Market Overview
  • 9.2. China Capecitabine Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Capecitabine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Capecitabine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Capecitabine Market

  • 10.1. India Capecitabine Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Capecitabine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Capecitabine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Capecitabine Market

  • 11.1. Japan Capecitabine Market Overview
  • 11.2. Japan Capecitabine Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Capecitabine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Capecitabine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Capecitabine Market

  • 12.1. Australia Capecitabine Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Capecitabine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Capecitabine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Capecitabine Market

  • 13.1. Indonesia Capecitabine Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Capecitabine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Capecitabine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Capecitabine Market

  • 14.1. South Korea Capecitabine Market Overview
  • 14.2. South Korea Capecitabine Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Capecitabine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Capecitabine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Capecitabine Market

  • 15.1. Western Europe Capecitabine Market Overview
  • 15.2. Western Europe Capecitabine Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Capecitabine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Capecitabine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Capecitabine Market

  • 16.1. UK Capecitabine Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Capecitabine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Capecitabine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Capecitabine Market

  • 17.1. Germany Capecitabine Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Capecitabine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Capecitabine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Capecitabine Market

  • 18.1. France Capecitabine Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Capecitabine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Capecitabine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Capecitabine Market

  • 19.1. Italy Capecitabine Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Capecitabine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Capecitabine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Capecitabine Market

  • 20.1. Spain Capecitabine Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Capecitabine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Capecitabine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Capecitabine Market

  • 21.1. Eastern Europe Capecitabine Market Overview
  • 21.2. Eastern Europe Capecitabine Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Capecitabine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Capecitabine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Capecitabine Market

  • 22.1. Russia Capecitabine Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Capecitabine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Capecitabine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Capecitabine Market

  • 23.1. North America Capecitabine Market Overview
  • 23.2. North America Capecitabine Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Capecitabine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Capecitabine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Capecitabine Market

  • 24.1. USA Capecitabine Market Overview
  • 24.2. USA Capecitabine Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Capecitabine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Capecitabine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Capecitabine Market

  • 25.1. Canada Capecitabine Market Overview
  • 25.2. Canada Capecitabine Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Capecitabine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Capecitabine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Capecitabine Market

  • 26.1. South America Capecitabine Market Overview
  • 26.2. South America Capecitabine Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Capecitabine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Capecitabine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Capecitabine Market

  • 27.1. Brazil Capecitabine Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Capecitabine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Capecitabine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Capecitabine Market

  • 28.1. Middle East Capecitabine Market Overview
  • 28.2. Middle East Capecitabine Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Capecitabine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Capecitabine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Capecitabine Market

  • 29.1. Africa Capecitabine Market Overview
  • 29.2. Africa Capecitabine Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Capecitabine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Capecitabine Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Capecitabine Market Competitive Landscape And Company Profiles

  • 30.1. Capecitabine Market Competitive Landscape
  • 30.2. Capecitabine Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Merck & Co. Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Bayer AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Novartis AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Sanofi S.A.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Capecitabine Market Other Major And Innovative Companies

  • 31.1. Sensus Healthcare Inc.
  • 31.2. Fresenius SE & Co. KGaA
  • 31.3. GlaxoSmithKline plc
  • 31.4. Eli Lilly and Company
  • 31.5. Teva Pharmaceutical Industries Ltd.
  • 31.6. Sun Pharmaceutical Industries Inc.
  • 31.7. Genentech Inc.
  • 31.8. Aurobindo Pharma Limited
  • 31.9. Dr Reddy Laboratories Ltd.
  • 31.10. Sigma-Aldrich Corp
  • 31.11. Cipla Inc.
  • 31.12. Hikma Pharmaceuticals plc
  • 31.13. Lupin Limited
  • 31.14. Alkem Laboratories Limited
  • 31.15. Ranbaxy Laboratories Ltd.

32. Global Capecitabine Market Competitive Benchmarking

33. Global Capecitabine Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Capecitabine Market

35. Capecitabine Market Future Outlook and Potential Analysis

  • 35.1 Capecitabine Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Capecitabine Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Capecitabine Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer